Analyses of therapeutic effects using rludarabine and cytarabine on acute myeloid leukemia at different stages during treatment  

FA方案用于急性髓系白血病不同治疗阶段疗效分析(英文)

作　　者：Na Xu Xiaoli Liu Qjngfeng Du Lingyun Ouyang Zhi Liu Lijun Hou 

机构地区：[1]Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China [2]Department of Hematology and Rheumatisis, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, China

出　　处：《The Chinese-German Journal of Clinical Oncology》2009年第6期349-352,共4页中德临床肿瘤学杂志（英文版）

基　　金：Supported by a grant from the Planned Science and Technology Project of Guangzhou (No. 2006Z3-E0401)

摘　　要：Objective: To evaluate the therapeutic effect of the fludarabine and cytarabine (FA) regimen on acute myeloid leukemia (AML) at different phases during treatment. Methods: A total of 185 patients with AML were divided into 4 groups based on the outcome of previous treatments. Patients in Group 1 had no remission after the first course of induction chemotherapy (n = 55). Patients in Group 2 had no remission after no less than two courses of induction chemotherapy (n = 41). Patients in Group 3 had early relapse (n = 40). Patients in Group 4 had late relapse (n = 49). Patients in groups 2, 3 and 4 had refractory AML or AML with relapse. We assessed the efficacy and toxicity of FA combination chemotherapy in each of these 4 groups. Results: The complete remission (CR) rates of Groups 1, 2, 3 and 4 were 74.5% (41/55), 45.9% (19/41), 17.5% (7/40) and 38.8% (19/49), respectively. The CR rate was higher in Group 1 than in the other 3 groups (34.6%, 45/130) (P = 0.000). A significant correlation was found between CR rate and the number of chemotherapeutic courses (P = 0.023). The main adverse reactions included bone marrow suppression and secondary infection. Conclusion: FA regimen is a good choice for patients with AML, especially those who have failed to achieve CR after the first course of induction chemotherapy.

关 键 词：acute myeloid leukemia （AML） FLUDARABINE CYTARABINE 

分 类 号：R733.71[医药卫生—肿瘤] R644[医药卫生—临床医学]